{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T14:24:30Z","timestamp":1791469470788,"version":"4.3.4"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T00:00:00Z","timestamp":1645660800000},"content-version":"am","delay-in-days":238,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000026","name":"NIDA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.jsat.2021.108329","type":"journal-article","created":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T21:29:55Z","timestamp":1613683795000},"page":"108329","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":144,"special_numbering":"C","title":["Who stays in medication treatment for opioid use disorder? A national study of outpatient specialty treatment settings"],"prefix":"10.1016","volume":"126","author":[{"given":"Noa","family":"Krawczyk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur Robin","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Saloner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Cerd\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsat.2021.108329_bb0005","doi-asserted-by":"crossref","unstructured":"Akaike, H. (1974). A New Look at the Statistical Model Identification (pp. 215\u2013222). doi:https:\/\/doi.org\/10.1007\/978-1-4612-1694-0_16.","DOI":"10.1007\/978-1-4612-1694-0_16"},{"key":"10.1016\/j.jsat.2021.108329_bb0010","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jsat.2016.08.002","article-title":"Non-prescribed buprenorphine in New York City: Motivations for use, practices of diversion, and experiences of stigma","volume":"70","author":"Allen","year":"2016","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2021.108329_bb0015","series-title":"Social & legal perspectives on underuse of medication-assisted treatment for opioid dependence","author":"Andraka-Christou","year":"2016"},{"issue":"1","key":"10.1016\/j.jsat.2021.108329_bb0020","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/jrh.12307","article-title":"Geographic distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: A 5-year update","volume":"35","author":"Andrilla","year":"2019","journal-title":"The Journal of Rural Health"},{"issue":"3","key":"10.1016\/j.jsat.2021.108329_bb0025","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1080\/10550887.2012.694602","article-title":"Housing first for severely mentally ill homeless methadone patients","volume":"31","author":"Appel","year":"2012","journal-title":"Journal of Addictive Diseases"},{"issue":"1","key":"10.1016\/j.jsat.2021.108329_bb0030","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1080\/00952990802342899","article-title":"A meta-analysis of retention in methadone maintenance by dose and dosing strategy","volume":"35","author":"Bao","year":"2009","journal-title":"The American Journal of Drug and Alcohol Abuse"},{"key":"10.1016\/j.jsat.2021.108329_bb0035","first-page":"1","article-title":"Comparing and evaluating substance use treatment utilization estimates from the National Survey on Drug Use and Health and other data sources","author":"Batts","year":"2014","journal-title":"CBHSQ Data Review"},{"key":"10.1016\/j.jsat.2021.108329_bb0040","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jsat.2014.12.011","article-title":"Discontinuation of buprenorphine maintenance therapy: Perspectives and outcomes","volume":"52","author":"Bentzley","year":"2015","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2021.108329_bb0045","series-title":"Management of opioid use disorder in the USA: Present status and future directions. Lancet","author":"Blanco","year":"2019"},{"issue":"5","key":"10.1016\/j.jsat.2021.108329_bb0050","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/add.14114","article-title":"Excess overdose mortality immediately following transfer of patients and their care as well as after cessation of opioid substitution therapy","volume":"113","author":"Bogdanowicz","year":"2018","journal-title":"Addiction"},{"issue":"2","key":"10.1016\/j.jsat.2021.108329_bb0055","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jsat.2005.11.007","article-title":"Slow tapering from methadone maintenance in a program encouraging indefinite maintenance","volume":"30","author":"Calsyn","year":"2006","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2021.108329_bb0060","unstructured":"Center for Behavioral Health Statistics, S. (2019). CBHSQ Data Review: Comparing and Evaluating Substance Use Treatment Utilization Estimates from the National Survey on Drug Use and Health and Other Data Sources. Retrieved October 31, 2019, from http:\/\/www.samhsa.gov\/data\/."},{"issue":"1\u20133","key":"10.1016\/j.jsat.2021.108329_bb0065","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.drugalcdep.2007.11.003","article-title":"Mortality prior to, during and after opioid maintenance treatment (OMT): A national prospective cross-registry study","volume":"94","author":"Clausen","year":"2008","journal-title":"Drug and Alcohol Dependence"},{"issue":"3","key":"10.1016\/j.jsat.2021.108329_bb0070","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jsat.2011.05.001","article-title":"Risk of drug-related mortality during periods of transition in methadone maintenance treatment: A cohort study","volume":"41","author":"Cousins","year":"2011","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"1","key":"10.1016\/j.jsat.2021.108329_bb0075","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jsat.2012.03.002","article-title":"Predictors of methadone program non-retention for opioid analgesic dependent patients","volume":"44","author":"Cox","year":"2013","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"1","key":"10.1016\/j.jsat.2021.108329_bb0080","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/BF02287327","article-title":"Retention in publicly funded methadone maintenance treatment in two western states","volume":"32","author":"Deck","year":"2005","journal-title":"Journal of Behavioral Health Services & Research"},{"issue":"12","key":"10.1016\/j.jsat.2021.108329_bb0085","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1001\/jamainternmed.2014.5302","article-title":"Primary care\u2013based buprenorphine taper vs maintenance therapy for prescription opioid dependence: A randomized clinical trial","volume":"174","author":"Fiellin","year":"2014","journal-title":"JAMA Internal Medicine"},{"issue":"2","key":"10.1016\/j.jsat.2021.108329_bb0090","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1080\/08897077.2013.819828","article-title":"A comparison of characteristics and outcomes of opioid-dependent patients initiating office-based buprenorphine or methadone maintenance treatment","volume":"35","author":"Fingerhood","year":"2014","journal-title":"Substance Abuse"},{"issue":"3","key":"10.1016\/j.jsat.2021.108329_bb0095","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1353\/hpu.2014.0139","article-title":"Health outcomes and retention in care following release from prison for patients of an urban post-incarceration transitions clinic","volume":"25","author":"Fox","year":"2014","journal-title":"Journal of Health Care for the Poor and Underserved"},{"key":"10.1016\/j.jsat.2021.108329_bb0100","doi-asserted-by":"crossref","unstructured":"Greenfield, L., Brady, J. V, Besteman, K. J., & De Smet, A. (1996). Patient retention in mobile and fixed-site methadone maintenance treatment. Drug and Alcohol Dependence, 42(2), 125\u2013131. doi:https:\/\/doi.org\/10.1016\/0376-8716(96)01273-2.","DOI":"10.1016\/0376-8716(96)01273-2"},{"issue":"3","key":"10.1016\/j.jsat.2021.108329_bb0105","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jsat.2013.10.004","article-title":"Leaving buprenorphine treatment: Patients\u2019 reasons for cessation of care","volume":"46","author":"Gryczynski","year":"2014","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2021.108329_bb0110","doi-asserted-by":"crossref","unstructured":"Harris, J., & McElrath, K. (2012). Methadone as social control: institutionalized stigma and the prospect of recovery. Qualitative Health Research, 22(6), 810\u2013824. doi:https:\/\/doi.org\/10.1177\/1049732311432718 [doi].","DOI":"10.1177\/1049732311432718"},{"issue":"1","key":"10.1016\/j.jsat.2021.108329_bb0115","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/add.12333","article-title":"Treatment retention among patients randomized to buprenorphine\/naloxone compared to methadone in a multi-site trial","volume":"109","author":"Hser","year":"2014","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2021.108329_bb0120","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.20843","article-title":"Differences in availability and use of medications for opioid use disorder in residential treatment settings in the United States","author":"Huhn","year":"2020","journal-title":"JAMA Network Open."},{"key":"10.1016\/j.jsat.2021.108329_bb0125","doi-asserted-by":"crossref","unstructured":"Jarvis, B. P., Holtyn, A. F., Subramaniam, S., Tompkins, D. A., Oga, E. A., Bigelow, G. E., & Silverman, K. (2018). Extended-release injectable naltrexone for opioid use disorder: a systematic review. Addiction, 113(7), 1188\u20131209). doi:https:\/\/doi.org\/10.1111\/add.14180.","DOI":"10.1111\/add.14180"},{"key":"10.1016\/j.jsat.2021.108329_bb0130","doi-asserted-by":"crossref","unstructured":"Jones, C. M., Underwood, N., & Compton, W. (2019). Increases in Methamphetamine Use among Heroin Treatment Admissions in the United States, 2008\u20132017. Addiction, add.14812. doi:https:\/\/doi.org\/10.1111\/add.14812.","DOI":"10.1111\/add.14812"},{"issue":"5","key":"10.1016\/j.jsat.2021.108329_bb0135","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1080\/10550490802266276","article-title":"Methadone maintenance vs. methadone taper during pregnancy: Maternal and neonatal outcomes","volume":"17","author":"Jones","year":"2008","journal-title":"American Journal on Addictions"},{"key":"10.1016\/j.jsat.2021.108329_bb0140","doi-asserted-by":"crossref","unstructured":"Kariisa, M., Scholl, L., Wilson, N., Seth, P., & Hoots, B. (2019). Drug overdose Deaths Involving Cocaine and Psychostimulants with Abuse Potential\u2014United States, 2003\u20132017. MMWR. Morbidity and Mortality Weekly Report, 68(17), 388\u2013395. doi:10.15585\/mmwr.mm6817a3.","DOI":"10.15585\/mmwr.mm6817a3"},{"issue":"2\u20133","key":"10.1016\/j.jsat.2021.108329_bb0145","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.drugalcdep.2011.01.008","article-title":"Predictors of methadone treatment retention from a multi-site study: A survival analysis","volume":"117","author":"Kelly","year":"2011","journal-title":"Drug and Alcohol Dependence"},{"issue":"3","key":"10.1016\/j.jsat.2021.108329_bb0150","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1080\/09595230500170241","article-title":"From opioid maintenance to abstinence: A literature review","volume":"24","author":"Korn\u00f8r","year":"2005","journal-title":"Drug and Alcohol Review"},{"key":"10.1016\/j.jsat.2021.108329_bb0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsat.2019.05.002","article-title":"Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: Addressing a critical care gap","volume":"103","author":"Krawczyk","year":"2019","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2021.108329_bb0160","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.drugalcdep.2017.06.009","article-title":"Racial and ethnic differences in opioid agonist treatment for opioid use disorder in a U.S. national sample","volume":"178","author":"Krawczyk","year":"2017","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2021.108329_bb0165","doi-asserted-by":"crossref","DOI":"10.1111\/add.14991","article-title":"Opioid agonist treatment and fatal overdose risk in a statewide population receiving opioid use disorder services","author":"Krawczyk","year":"2020","journal-title":"Addiction."},{"issue":"12","key":"10.1016\/j.jsat.2021.108329_bb0170","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1377\/hlthaff.2017.0890","article-title":"Only one in twenty justice-referred adults in specialty treatment for opioid use receive methadone or buprenorphine","volume":"36","author":"Krawczyk","year":"2017","journal-title":"Health Affairs (Project Hope)"},{"key":"10.1016\/j.jsat.2021.108329_bb0175","doi-asserted-by":"crossref","first-page":"107997","DOI":"10.1016\/j.drugalcdep.2020.107997","article-title":"Opioid overdose death following criminal justice involvement: Linking statewide corrections and hospital databases to detect individuals at highest risk","volume":"213","author":"Krawczyk","year":"2020","journal-title":"Drug and Alcohol Dependence."},{"key":"10.1016\/j.jsat.2021.108329_bb0180","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.drugalcdep.2017.02.006","article-title":"The association of psychiatric comorbidity with treatment completion among clients admitted to substance use treatment programs in a U.S. national sample","volume":"175","author":"Krawczyk","year":"2017","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2021.108329_bb0185","doi-asserted-by":"crossref","unstructured":"Krawczyk, Noa, Mojtabai, R., Stuart, E. A., Fingerhood, M. I., Agus, D., Lyons, B. C., Weiner, J. P., & Saloner, B. (2020a). Opioid agonist treatment is highly protective against overdose death among a U.S. statewide population of justice-involved adults. Doi:https:\/\/doi.org\/10.1080\/00952990.2020.1828440. doi:https:\/\/doi.org\/10.1080\/00952990.2020.1828440.","DOI":"10.1080\/00952990.2020.1828440"},{"key":"10.1016\/j.jsat.2021.108329_bb0190","doi-asserted-by":"crossref","DOI":"10.1080\/08897077.2018.1439798","article-title":"Overcoming medication stigma in peer recovery: A new paradigm","author":"Krawczyk","year":"2018","journal-title":"Substance Abuse."},{"key":"10.1016\/j.jsat.2021.108329_bb0195","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jsat.2015.01.009","article-title":"Gender-specific predictors of retention and opioid abstinence during methadone maintenance treatment","volume":"54","author":"Levine","year":"2015","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2021.108329_bb0200","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jsat.2017.04.002","article-title":"Extended-release naltrexone for opioid use disorder started during or following incarceration","volume":"85","author":"Lincoln","year":"2018","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"1","key":"10.1016\/j.jsat.2021.108329_bb0205","first-page":"62","article-title":"Leaving methadone treatment: Lessons learned, lessons forgotten, lessons ignored","volume":"68","author":"Magura","year":"2001","journal-title":"The Mount Sinai Journal of Medicine, New York"},{"issue":"9","key":"10.1016\/j.jsat.2021.108329_bb0210","doi-asserted-by":"crossref","first-page":"628","DOI":"10.7326\/M18-1652","article-title":"The next stage of buprenorphine care for opioid use disorder: A narrative review","volume":"169","author":"Martin","year":"2018","journal-title":"Annals of Internal Medicine."},{"key":"10.1016\/j.jsat.2021.108329_bb0215","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jsat.2019.07.010","article-title":"Prescribing decisions at buprenorphine treatment initiation: Do they matter for treatment discontinuation and adverse opioid-related events?","volume":"105","author":"Meinhofer","year":"2019","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"9","key":"10.1016\/j.jsat.2021.108329_bb0220","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/j.1360-0443.2010.02990.x","article-title":"Meta-analysis of drug-related deaths soon after release from prison","volume":"105","author":"Merrall","year":"2010","journal-title":"Addiction"},{"issue":"1","key":"10.1016\/j.jsat.2021.108329_bb0225","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1377\/hlthaff.2018.05162","article-title":"Medication treatment for opioid use disorders in substance use treatment facilities","volume":"38","author":"Mojtabai","year":"2019","journal-title":"Health Affairs"},{"key":"10.1016\/j.jsat.2021.108329_bb0230","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jsat.2017.07.001","article-title":"Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population","volume":"85","author":"Morgan","year":"2018","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2021.108329_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2019.02.031","article-title":"Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort","author":"Morgan","year":"2019","journal-title":"Drug and Alcohol Dependence."},{"key":"10.1016\/j.jsat.2021.108329_bb0240","unstructured":"National Quality Forum. (2017). Behavioral Health 2016\u20132017 Final Report. https:\/\/www.qualityforum.org\/Publications\/2017\/08\/Behavioral_Health_2016-2017_Final_Report.aspx."},{"issue":"1","key":"10.1016\/j.jsat.2021.108329_bb0245","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jsat.2014.06.006","article-title":"Buprenorphine pharmacotherapy and behavioral treatment: Comparison of outcomes among prescription opioid users, heroin users and combination users","volume":"48","author":"Nielsen","year":"2015","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2021.108329_bb0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.puhe.2017.03.002","article-title":"\u201cWhen you are homeless, you are not thinking about your medication, but your food, shelter or heat for the night\u201d: Behavioural determinants of homeless patients\u2019 adherence to prescribed medicines","volume":"148","author":"Paudyal","year":"2017","journal-title":"Public Health"},{"key":"10.1016\/j.jsat.2021.108329_bb0255","doi-asserted-by":"crossref","unstructured":"Polsky, D., Arsenault, S., & Azocar, F. (2019). Private Coverage of Methadone in Outpatient Treatment Programs. Psychiatric Services, appi.ps.2019003. doi:https:\/\/doi.org\/10.1176\/appi.ps.201900373.","DOI":"10.1176\/appi.ps.201900373"},{"issue":"4","key":"10.1016\/j.jsat.2021.108329_bb0260","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1037\/adb0000090","article-title":"Predictors of patient retention in methadone maintenance treatment","volume":"29","author":"Proctor","year":"2015","journal-title":"Psychology of Addictive Behaviors"},{"issue":"2","key":"10.1016\/j.jsat.2021.108329_bb0265","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1080\/02791072.2017.1300360","article-title":"Commercial health plan coverage of selected treatments for opioid use disorders from 2003 to 2014","volume":"49","author":"Reif","year":"2017","journal-title":"Journal of Psychoactive Drugs"},{"issue":"3","key":"10.1016\/j.jsat.2021.108329_bb0270","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/02791072.2009.10400539","article-title":"Premature discharge from methadone treatment: Patient perspectives","volume":"41","author":"Reisinger","year":"2009","journal-title":"Journal of Psychoactive Drugs"},{"issue":"1","key":"10.1016\/j.jsat.2021.108329_bb0275","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1370\/afm.1735","article-title":"Geographic and specialty distribution of US physicians trained to treat opioid use disorder","volume":"13","author":"Rosenblatt","year":"2015","journal-title":"Annals of Family Medicine"},{"key":"10.1016\/j.jsat.2021.108329_bb0280","doi-asserted-by":"crossref","unstructured":"Rosenblum, A., Cleland, C. M., Fong, C., Kayman, D. J., Tempalski, B., & Parrino, M. (2011). Distance traveled and cross-state commuting to opioid treatment programs in the United States. Journal of Environmental and Public Health, 2011, 948789. doi:https:\/\/doi.org\/10.1155\/2011\/948789 [doi].","DOI":"10.1155\/2011\/948789"},{"key":"10.1016\/j.jsat.2021.108329_bb0285","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.addbeh.2015.04.006","article-title":"Evaluating racial disparity in referral source and successful completion of substance abuse treatment","volume":"48","author":"Sahker","year":"2015","journal-title":"Addictive Behaviors"},{"key":"10.1016\/j.jsat.2021.108329_bb0290","doi-asserted-by":"crossref","unstructured":"Saloner, B., & Cook, B. L. (2013). Blacks and Hispanics are less likely than whites to complete addiction treatment, largely due to socioeconomic factors. Health Affairs (Project Hope), 32(1), 135\u2013145. doi:https:\/\/doi.org\/10.1377\/hlthaff.2011.0983 [doi].","DOI":"10.1377\/hlthaff.2011.0983"},{"issue":"7","key":"10.1016\/j.jsat.2021.108329_bb0295","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/MLR.0000000000000727","article-title":"Patterns of buprenorphine-naloxone treatment for opioid use disorder in a multistate population","volume":"55","author":"Saloner","year":"2017","journal-title":"Medical Care"},{"key":"10.1016\/j.jsat.2021.108329_bb0300","unstructured":"SAMHSA. (2019a). TIP 63: Medications for Opioid Use Disorder. https:\/\/store.samhsa.gov\/product\/TIP-63-Medications-for-Opioid-Use-Disorder-Full-Document-Including-Executive-Summary-and-Parts-1-5-\/SMA19-5063FULLDOC."},{"key":"10.1016\/j.jsat.2021.108329_bb0305","unstructured":"SAMHSA. (2019b). Treatment Episode Data Set (TEDS): 2007-2017. doi:HHS Publication No. (SMA) 17-4360."},{"key":"10.1016\/j.jsat.2021.108329_bb0310","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jsat.2018.09.001","article-title":"Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees","volume":"95","author":"Samples","year":"2018","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2021.108329_bb0315","doi-asserted-by":"crossref","unstructured":"Scholl, L., Seth, P., Kariisa, M., Wilson, N., & Baldwin, G. (2019). Drug and Opioid-Involved Overdose Deaths \u2014 United States, 2013\u20132017. MMWR. Morbidity and Mortality Weekly Report, 67(5152). doi:10.15585\/mmwr.mm6751521e1.","DOI":"10.15585\/mmwr.mm675152e1"},{"issue":"3","key":"10.1016\/j.jsat.2021.108329_bb0320","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jsat.2014.04.006","article-title":"Emerging adult age status predicts poor buprenorphine treatment retention","volume":"47","author":"Schuman-Olivier","year":"2014","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"4","key":"10.1016\/j.jsat.2021.108329_bb0325","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1001\/jamapsychiatry.2013.4450","article-title":"Access to treatment for opioid dependence in rural America: Challenges and future directions","volume":"71","author":"Sigmon","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jsat.2021.108329_bb0330","series-title":"Stata statistical software: Release 15","author":"StataCorp","year":"2017"},{"issue":"4","key":"10.1016\/j.jsat.2021.108329_bb0335","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/08897077.2018.1449166","article-title":"A population-based examination of trends and disparities in medication treatment for opioid use disorders among Medicaid enrollees","volume":"39","author":"Stein","year":"2018","journal-title":"Substance Abuse"},{"issue":"1","key":"10.1016\/j.jsat.2021.108329_bb0340","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/10550887.2016.1100960","article-title":"Retention in medication-assisted treatment for opiate dependence: A systematic review","volume":"35","author":"Timko","year":"2016","journal-title":"Journal of Addictive Diseases"},{"key":"10.1016\/j.jsat.2021.108329_bb0345","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.addbeh.2019.01.020","article-title":"Challenges on the road to recovery: Exploring attitudes and experiences of clients in a community-based buprenorphine program in Baltimore City","volume":"93","author":"Truong","year":"2019","journal-title":"Addictive Behaviors"},{"key":"10.1016\/j.jsat.2021.108329_bb0350","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jsat.2019.10.005","article-title":"Association between methamphetamine use and retention among patients with opioid use disorders treated with buprenorphine","volume":"109","author":"Tsui","year":"2020","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"14\u201315","key":"10.1016\/j.jsat.2021.108329_bb0355","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1002\/sim.4780111409","article-title":"The accelerated failure time model: A useful alternative to the cox regression model in survival analysis","volume":"11","author":"Wei","year":"1992","journal-title":"Statistics in Medicine"},{"issue":"4","key":"10.1016\/j.jsat.2021.108329_bb0360","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/sim.4067","article-title":"Multiple imputation using chained equations: Issues and guidance for practice","volume":"30","author":"White","year":"2011","journal-title":"Statistics in Medicine"},{"key":"10.1016\/j.jsat.2021.108329_bb0365","first-page":"61","author":"White","year":"2011","journal-title":"Narcotics Anonymous and the Pharmacotherapeutic Treatment of Opioid Addiction in the United States."},{"key":"10.1016\/j.jsat.2021.108329_bb0370","series-title":"New England Journal of Medicine, 375 (9), 813\u2013815","article-title":"From AIDS to opioids - how to combat an epidemic","author":"Williams","year":"2016"},{"issue":"1","key":"10.1016\/j.jsat.2021.108329_bb0375","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/00952990.2018.1546862","article-title":"Development of a cascade of care for responding to the opioid epidemic","volume":"45","author":"Williams","year":"2019","journal-title":"The American Journal of Drug and Alcohol Abuse"},{"key":"10.1016\/j.jsat.2021.108329_bb0380","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jsat.2018.06.001","article-title":"Developing an opioid use disorder treatment cascade: A review of quality measures","volume":"91","author":"Williams","year":"2018","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2021.108329_bb0385","article-title":"Acute care, prescription opioid use, and overdose following discontinuation of long-term buprenorphine treatment for opioid use disorder","author":"Williams","year":"2019","journal-title":"American Journal of Psychiatry."}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547221000556?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547221000556?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:53:40Z","timestamp":1760039620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547221000556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":77,"alternative-id":["S0740547221000556"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2021.108329","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Who stays in medication treatment for opioid use disorder? A national study of outpatient specialty treatment settings","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2021.108329","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108329"}}